I think this is a critical piece of information because really that first step is performing validation to ensure that the platform is robust, that with a human in the loop process, we always want to make sure we have our research coordinators and physicians involved in that process to ensure that we have high performance of the platform. The current step that we actually just went live with a couple of weeks ago is a prospective randomized trial...
I think this is a critical piece of information because really that first step is performing validation to ensure that the platform is robust, that with a human in the loop process, we always want to make sure we have our research coordinators and physicians involved in that process to ensure that we have high performance of the platform. The current step that we actually just went live with a couple of weeks ago is a prospective randomized trial. So we’re here, we’re actually randomizing patients to go through the AI platform or not, and then comparing how many patients actually get pre-screened by using standard of care processes versus AI-driven processes. How many of those patients ultimately consent onto a trial? And this could be a number of treatment, therapeutic trials, non-treatment trials, supportive care-related studies, biomarker studies. So we’re actually doing this across a wide array of our platforms. And ultimately, the goal is to try to get more patients enrolled onto these studies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
